KRAS and neoplasm: Thus, tumours with STK11 mutations seem to be associated with a worse outcome of ICB therapy and it has also been shown that co‐occurrence of STK11 with, for example, KEAP1 or KRAS may be prognostic rather than predictive.37, 38